Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Quote. Real-time Tradegate - 01/21 04:55:25 am
80.51 EUR   +0.16%
01/14UCB : S.A - Transparency notification BlackRock, Inc
AQ
01/14UCB : S.A. - Disposal of own shares
AQ
01/13UCB : Transparency notification BlackRock, Inc.
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

UCB : Belgium's UCB raises 2019 forecasts after net sales beat in fourth quarter

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/10/2020 | 12:53pm EST
The logo of Belgian drug, chemical, and plastics group UCB is seen at the entrance of the company's headquarters in Brussels

Belgian drugmaker UCB raised its revenue and earnings per share guidance for 2019 on Friday, helped by better-than-expected net sales due to strong demand for its Cimzia and Vimpat drugs in the fourth quarter.

Full-year revenue is expected now at about 4.9 billion euros (4.2 billion pounds), above the previously expected range of 4.6–4.7 billion euros, and UCB targets now EPS higher than 4.80 euro, it said in a statement.

The company, which now also sees recurring core profit at least at the upper end of its range of 27-29%, said it funded additional marketing activities to optimize the growth opportunity.

(Reporting by Pawel Goraj)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
01/14UCB : S.A - Transparency notification BlackRock, Inc
AQ
01/14UCB : S.A. - Disposal of own shares
AQ
01/13UCB : Transparency notification BlackRock, Inc.
PU
01/13UCB : Disposal of own shares
PU
01/13UCB : Threshold crossings
CO
01/10UCB : Belgium's UCB raises 2019 forecasts after net sales beat in fourth quarter
RE
01/10UCB : updates its financial outlook for 2019
PU
01/08UCB : S.A. - Transparency notification BlackRock, Inc
AQ
01/07UCB : Transparency notification BlackRock, Inc.
PU
01/07UCB : Threshold crossings
CO
More news
Financials (EUR)
Sales 2019 4 795 M
EBIT 2019 1 113 M
Net income 2019 779 M
Finance 2019 395 M
Yield 2019 1,46%
P/E ratio 2019 19,5x
P/E ratio 2020 19,2x
EV / Sales2019 3,08x
EV / Sales2020 3,07x
Capitalization 15 141 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 86,30  €
Last Close Price 80,38  €
Spread / Highest target 28,1%
Spread / Average Target 7,36%
Spread / Lowest Target -11,7%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB13.37%16 780
CSL LIMITED8.83%93 690
BIOGEN INC.-3.78%51 516
ALEXION PHARMACEUTICALS4.73%25 066
SAMSUNG BIOLOGICS CO LTD--.--%24 915
GRIFOLS1.53%21 142